SteelPeak Wealth LLC Has $7.40 Million Holdings in Merck & Co., Inc. (NYSE:MRK)

SteelPeak Wealth LLC boosted its position in Merck & Co., Inc. (NYSE:MRK) by 115.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 64,699 shares of the company’s stock after buying an additional 34,706 shares during the period. SteelPeak Wealth LLC’s holdings in Merck & Co., Inc. were worth $7,395,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in MRK. Itau Unibanco Holding S.A. acquired a new position in shares of Merck & Co., Inc. during the second quarter valued at about $39,000. Abich Financial Wealth Management LLC grew its holdings in shares of Merck & Co., Inc. by 121.8% in the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after acquiring an additional 179 shares in the last quarter. Quarry LP purchased a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $42,000. Strategic Financial Concepts LLC lifted its holdings in Merck & Co., Inc. by 1,475.6% during the second quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock worth $43,000 after acquiring an additional 32,832 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its position in Merck & Co., Inc. by 47.5% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock worth $43,000 after purchasing an additional 122 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Up 0.0 %

MRK stock traded up $0.02 during midday trading on Wednesday, hitting $103.75. The stock had a trading volume of 4,172,149 shares, compared to its average volume of 8,767,140. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.47 and a quick ratio of 1.22. The firm has a market cap of $262.78 billion, a price-to-earnings ratio of 19.23, a price-to-earnings-growth ratio of 1.49 and a beta of 0.39. The business has a 50-day moving average of $113.09 and a two-hundred day moving average of $121.28. Merck & Co., Inc. has a 52-week low of $99.80 and a 52-week high of $134.63.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, July 30th. The company reported $2.28 EPS for the quarter, beating the consensus estimate of $2.16 by $0.12. Merck & Co., Inc. had a return on equity of 40.69% and a net margin of 21.99%. The company had revenue of $16.10 billion for the quarter, compared to analysts’ expectations of $15.87 billion. During the same period last year, the firm posted ($2.06) earnings per share. Merck & Co., Inc.’s revenue was up 7.1% compared to the same quarter last year. As a group, equities research analysts forecast that Merck & Co., Inc. will post 7.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of recent analyst reports. Evercore ISI upgraded Merck & Co., Inc. to a “strong-buy” rating in a research note on Tuesday, July 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc. in a report on Thursday, October 3rd. Citigroup cut their price objective on shares of Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Barclays decreased their target price on shares of Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating on the stock in a report on Monday, October 7th. Finally, Sanford C. Bernstein initiated coverage on shares of Merck & Co., Inc. in a report on Thursday, October 17th. They issued a “market perform” rating and a $115.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating, nine have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus target price of $131.46.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.